Loading organizations...
ALS Finding a Cure is an organization dedicated to funding and accelerating research aimed at discovering treatments and a cure for Amyotrophic Lateral Sclerosis. It focuses its efforts on identifying novel biomarkers and diagnostics, advancing new therapies into clinical trials, and fostering innovation in trial design. The organization strategically invests its substantial budget across target identification, resource facilitation, and clinical studies to bridge critical gaps in scientific understanding.
The initiative was co-founded by Leandro P. Rizzuto and Peter Foss, driven by Leandro's personal experience with his son and daughter-in-law's battle against ALS. Conceived after Christie Rizzuto's diagnosis in 2009, Rizzuto envisioned a collaborative effort bringing together experts from diverse medical and scientific fields. Operating as a program of the Leandro P. Rizzuto Foundation, the organization was established with the insight that a concerted, multidisciplinary approach was essential to overcome existing research hurdles.
ALS Finding a Cure primarily serves the global medical research community, providing vital funding and fostering open collaboration among neurologists and neuroscientists. Ultimately, its work benefits individuals living with ALS, their families, and caregivers by striving to deliver effective diagnostics and therapies. The organization’s long-term vision centers on accelerating scientific breakthroughs to achieve a cure for ALS, aiming for earlier identification and improved treatment outcomes for all affected.
ALS Finding a Cure has 2 tracked investments across 1 company. The latest tracked deal is $17.0M Series B in Emulate in October 2016.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 1, 2016 | Emulate | $17.0M Series B | — | Biomatics Capital Partners, Illumina Ventures, NanoDimension, Paladin Capital Group, Rich Simoni, Hansjoerg Wyss, Atel Ventures, Cedars Sinai Medical Center, Labcorp, NanoDimension, OS Fund |
| Mar 28, 2016 | Emulate | $28.0M Series B | — | Hansjoerg Wyss, Atel Ventures, Cedars Sinai Medical Center, NanoDimension, OS Fund |